{"organizations": [], "uuid": "df15691f0ef5fb9611fc432279f1da1b18b2c421", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.marketwatch.com", "main_image": "http://s.wsj.net/public/resources/MWimages/MW-DR328_mw_soc_NS_20150801233302.png", "site_section": "http://finance.yahoo.com/news/provider-marketwatch/", "section_title": "MarketWatch News Archive - Yahoo! Finance", "url": "http://www.marketwatch.com/story/eli-lillys-stock-surges-on-heavy-volume-after-positive-drug-test-results-2015-08-20", "country": "US", "title": "Eli Lilly's stock surges on heavy volume after positive drug test results", "performance_score": 0, "site": "marketwatch.com", "participants_count": 2, "title_full": "Eli Lilly's stock surges on heavy volume after positive drug test results - MarketWatch", "spam_score": 0.0, "site_type": "news", "published": "2015-08-20T03:00:00.000+03:00", "replies_count": 1, "uuid": "b3aedcdc732b9fa71c9185bc94c83d94074b1599"}, "author": "Tomi Kilgore", "url": "http://www.marketwatch.com/story/eli-lillys-stock-surges-on-heavy-volume-after-positive-drug-test-results-2015-08-20#post-0", "ord_in_thread": 0, "title": "Eli Lilly's stock surges on heavy volume after positive drug test results", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Eli Lilly & Co.'s stock LLY, +4.46% climbed 4.6% in active midday trade, enough to make it the second-biggest percentage gainer within the S&P 500, after the drug maker and Boehringer Ingelheim announced positive test results for their diabetes treatment, Jardiance. Volume was 4 million shares, nearly double the full-day average of 2.3 million share, according to FactSet. Eli Lilly and Boehringer said Jardiance demonstrated cardiovascular (CV) risk reduction in people with type-2 diabetes at high risk for CV events. \"This comes as a surprise as no diabetes drugs, including insulin, have demonstrated CV benefit previously in the time frame of this study (average treatment [about] three years),\" Leerink Partners analyst Seamus Fernandez wrote in a note to clients. He said he believe this was \"significantly positive\" for Eli Lilly's diabetes franchise.", "external_links": [], "published": "2015-08-20T03:00:00.000+03:00", "crawled": "2015-08-20T21:37:11.904+03:00", "highlightTitle": ""}